Trade ACTU stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Actuate Therapeutics, Inc. (ACTU) is trading at US$0.64, up 5.49% today as of Oct 12, 16:00 EDT. The company has a market capitalisation of US$30.5M. Over the past 52 weeks, ACTU has traded between US$0.60 and US$8.30. On Syfe you can trade ACTU with $0 commission and add it to your watchlist.
| Previous close | US$0.61 |
|---|---|
| Market cap | US$30.5M |
| 52-week range | US$0.60 – US$8.30 |
| Volume | 269.2K |
| Exchange | US |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Year: 2024
Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma
Jun 9, 12:25 PM · MT Newswires
Actuate Therapeutics, Inc. (ACTU) stock is trading at US$0.64, +5.49% from the previous close of US$0.61.
The market cap for Actuate Therapeutics, Inc. (ACTU) stock is approximately US$30.5M.
The 52-week high for Actuate Therapeutics, Inc. (ACTU) stock is US$8.30.
The 52-week low for Actuate Therapeutics, Inc. (ACTU) stock is US$0.60.
Actuate Therapeutics, Inc. (ACTU) does not currently pay a dividend.
Stay on top of ACTU
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
